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Various methods for the direct reprogramming of human somatic cells have been developed. However, a
therapeutic method to reprogram and eliminate human solid tumor cells has not been developed. Here we
show anoveltherapeutic methodtoreprogram and eliminate human solidtumorcells withchemicals. This
therapeutic method may be applicable to various human solid tumor cells that express aldo-keto reductase
family 1 member B10 (AKR1B10) and retinoid X receptors (RXRs).
V
arious methods for the direct reprogramming of human somatic cells have been developed
1. However,
therapeutic methods to reprogram and destroy human solid tumor cells have not been developed.
The acyclic retinoid (ACR) was found to reduce the rate of recurrence after curative hepatocellular carcinoma
(HCC)therapyinasmallrandomizedcontrolledtrial(n589)
2,andsimilarresultswereobservedinarecentlarger
(n5401) randomized controlled trial
3. The hazard ratio (ACR versus placebo) for 2 years or more after curative
therapy was 0.27 (95% CI: 0.07–0.96)
3. However, ACR failed to suppress recurrence within 1–2 years following
curative therapy
3. The hazard ratio (ACR versus placebo) for within 1 year of curative therapy was 0.72 (95% CI:
0.45–1.17)
3. It has been postulated that aldo-keto reductase family 1 member B10 (AKR1B10)
4 inhibits retinoic
acid (RA)-induced cellular differentiation
5; however, this hypothesis has not been proven.
Results
AKR1B10 expression in liver cancer cells from patients with HCC who received a liver transplantation.
Following the methods previously described by our group and others
4 (cf. Methods), we investigated the
expression of AKR1B10 in liver cancer cells from 10 patients with HCC who received a liver transplantation
6.
AKR1B10 expression was observed in 6 of the patients with HCC (Figure 1a, 1b and Supplementary Figure 1a).
In vitro anticancer drug sensitivity testing in the 6 patients with HCC who expressed AKR1B10. In vitro
anticancer drug sensitivity testing was performed for the 6 patients with HCC who expressed AKR1B10 (cf.
Methods). At 6 days, a significant difference was observed in the viability of AKR1B10-positive liver cancer cells
treatedwithACRaloneandthosetreatedwithACRpluszopolrestat,whichisanAKR1B10inhibitor
7(Figure2A;
P,0.001,Mann-WhitneyUtest).Asignificantdifferencewasalsoobservedat6daysintheviabilityofAKR1B10-
positive liver cancer cells treated with zopolrestat alone and those treated with ACR plus zopolrestat (Figure 2A;
P,0.001,Mann-WhitneyUtest).Moreover,themeanalpha-fetoprotein(AFP)valueat3daysinsamplestreated
with ACR alone was 45.3 ng 6 5.2 ng/L 3 10
4 cells/24 h, while samples treated with ACR plus zopolrestat
showed an improved value of 3.6 ng 6 2.2 ng/L 3 10
4 cells/24 h (P,0.001, Mann-Whitney U test). The mean
albumin value at 3 days in samples treated with ACR alone was 19.3 ng 6 7.3 ng/L 3 10
4 cells/24 h, while
samples treated with ACR plus zopolrestat showed a significantly improved value of 93.3 ng 6 3.0 ng/L 3 10
4
cells/24 h (P50.02, Mann-Whitney U test).
Invitroanticancerdrugsensitivitytestinginthe4patientswithHCCwhodidnotexpressAKR1B10.Invitro
anticancer drug sensitivity testing was also performed in the 4 patients with HCC who did not express AKR1B10
(cf. Methods). At 6 days, a significant difference was observed in the viability of AKR1B10-negative liver cancer
cellstreatedwithACRaloneandthose treatedwithACRpluszopolrestat(Figure 2B;P50.02,Mann-Whitney U
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viability of AKR1B10-negative liver cancer cells treated with zopo-
lrestat and those treated with ACR plus zopolrestat (Figure 2B;
P,0.001, Mann-Whitney U test). Moreover, the mean AFP value
at 3 days in samples treated with ACR alone was 50.3 ng 6 6.5 ng/L
3 10
4 cells/24 h, while the mean value in samples treated with ACR
plus zopolrestat was improved at 7.6 ng 6 3.5 ng/L 3 10
4 cells/24 h
(P50.01, Mann-Whitney U test). The mean albumin value at 3 days
in samples treated with ACR alone was 17.1 ng 6 5.2 ng/L 3 10
4
cells/24 h, while the mean value in samples treated with ACR plus
zopolrestat was significantly improved at 85.3 ng 6 3.9 ng/L 3 10
4
cells/24 h (P50.02, Mann-Whitney U test).
Oxygen consumption in liver cancer cells. Aerobic respiration in
AKR1B10-positive liver cancer cells was assessed 3 days after
the administration of ACR alone, zopolrestat alone or ACR plus
zopolrestat. Oxygen consumption was significantly greater in
the AKR1B10-positive liver cancer cells treated with ACR plus
zopolrestat than in the cells treated with either ACR alone or
zopolrestat alone (Figure 3A; P,0.001, Mann-Whitney U test).
Aerobic respiration in the AKR1B10-negative liver cancer cells
was also assessed 3 days after the administration of ACR alone,
zopolrestat alone and ACR plus zopolrestat. Oxygen consumption
was significantly greater in AKR1B10-negative liver cancer cells
treated with ACR plus zopolrestat than in the cells treated with
either ACR alone or zopolrestat alone (Figure 3B; P,0.001, Mann-
Whitney U test).
Discussion
HCC has a high recurrence rate (49% in 38 months after curative
therapy) and a poor prognosis
2–3; no effective treatment has been
establishedforrecurrentHCC
2–3.Thisstudyoftheinvitroanticancer
drug sensitivity of AKR1B10-positive cells from patients with HCC
and ACR resistance (Figures 2A and 3A) suggests that AKR1B10-
positive patients with HCC and ACR resistance should be treated
with ACR plus zopolrestat rather than with ACR alone to reduce
HCC recurrence. Moreover, our experimental results support
the hypothesis
5 that AKR1B10 inhibits the cellular differentiation
induced by RA.
AKR1B10 has been reported to act as the major retinaldehyde
reductase, thereby decreasing cellular levels of RA
8–11. This action
may be the molecular basis underlying the combined effects of
ACR plus zopolrestat. However, no studies have reported that
AKR1B10 acts on RA or ACR. Therefore, although it is reasonable
to postulate that zopolrestat inhibits AKR1B10 in human HCC cells
Figure 1 | (a)The expression ofAKR1B10 by Western blot analysis inliver
cancer cells from patients with HCC (n56) who received a liver
transplantation. Samples from the other patients (n54) were AKR1B10-
negative.b-actinisshownasacontrol.(b)Quantitativereal-timePCRdata
of AKR1B10 in liver cancer cells from patients with HCC who received a
liver transplantation (n510).
Figure 2 | (A) AKR1B10-positive liver cancer cell viability after 6 days. (B)
AKR1B10-negative liver cancer cell viability after 6 days.
www.nature.com/scientificreports
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anism cannot be adapted to the combination of ACR plus an
AKR1B10 inhibitor unless we can demonstrate that AKR1B10 has
ACR reductase activity. Considering these points and our experi-
mental results, we believe that the combined effects of ACR plus
zopolrestat can be attributed to the synergism between ACR and 9-
cis-RA
12–13, in which ACR prevented hyperphosphorylation and the
inactivation of RXRa, and thereby restored 9-cis-RA activity. Thus,
zopolrestat may prevent endogenous 9-cis-RA depletion, whereas
ACR prevents RXRa inactivation. The AFP and albumin values in
AKR1B10-positiveornegativelivercancercellsimprovedaftertreat-
ment with ACR plus zopolrestat, and approached the values that
are expected from normal hepatocytes. Moreover, as described by
Otto Warburg in 1931, although cancer cells preferentially utilize
glycolytic pathways for energy generation while downregulating
their aerobic respiratory activity
14, oxygen consumption in
AKR1B10-positive or -negative liver cancer cells increased with
ACR plus zopolrestat (Figures 3A and 3B). Therefore, the combined
effects of ACR plus zopolrestat may work efficiently in the direct
reprogramming and destruction of human HCC cells. In addition,
our results suggest that even in patients with HCC and ACR resist-
ance who possess AKR1B10-negative liver cancer cells, ACR plus
zopolrestat therapy would be desirable to reduce the rate of recur-
rence of HCC (Figures 2B and 3B).
This therapeutic method may also be applicable to other human
solid tumor cells (i.e., HCC cells, non–small cell lung cancer cells
from smokers
4 or cervical cancer cells
15, etc.) that express AKR1B10
and RXRs. However, in the near future, clinical studies and/or clin-
ical trials will be necessary to investigate the efficacy and safety of
ACR plus zopolrestat for human solid tumor cells that express
AKR1B10 and RXRs.
In conclusion, these results confirm that liver cancer cells with
ACR resistance were directly reprogrammed to approximate normal
human hepatocytes, and ACR plus zopolrestat induced apoptosis
(Figures 2A, 2B, 3A and 3B). Therefore, a therapeutic method to
reprogramanddestroyhumansolidtumorcellswithchemicalsalone
has been developed.
Methods
Chemicals. Acyclic retinoid (all trans-3,7,11,15-tetramethyl-2,4,6,10,14-
hexadecapentaenoic acid: ACR) and zopolrestat were provided by Kowa (Tokyo,
Japan).
Patients. In our study, 10 liver cancer samples were obtained with informed consent
from patients who underwent a liver transplantation at our institutions (Ref. 6). The
10patientswithHCCbeforealivertransplantation(Ref.6)hadanagerangeof34–60
years (median: 55.7). All of the males (n57) were diagnosed with stage II cancer and
were HCV-positive with a Child-Pugh score of A; all of the females (n53) were
diagnosed withstageIIIcancer andwereHCV-positive withaChild-PughscoreofB.
A statement identifying the institutional and/or licensing committee
experimental approval. The study was approved by the Institutional Review Boards
ofourinstitutions(Harvard MedicalSchool,theUniversity ofTokyo,TokyoMedical
and Dental University), and informed written consent was obtained from all of the
patients.
TheevaluationofAKR1B10expression.Weusedapreviouslydescribedmethod
4to
investigate AKR1B10 expression in liver cancer cells from 10 patients with HCC who
received a liver transplantation
6. In this study, an AKR1B10 antibody (monoclonal
rabbit anti-human AKR1B10 antibody, clone 1A6; Abnova Corporation) was used.
AKR1B10 was evaluated in the human HCC samples according to the number of
positively stained tumor cells. If none of the tumor cells demonstrated AKR1B10
immunostaining, thesample wasconsideredtobeAKR1B10-negative.Thefollowing
primer and probes were used: Sequence (59 to 39)
AKR1B10-F: CATATCCAGAGGAATGTGATTGTCA;
AKR1B10-R: AGACCTGAATGTTCTCAACAATGC
In vitro anticancer drug sensitivity testing for the 10 patients with HCC. The liver
cancer cells were incubated in a flask coated with collagengelin a CO2incubatorat37uC
for 24 h. Only the viable cells adhering to the collagen gel were collected and
resuspended in the reconstituted type 1 collagen solution for a final density of
1310
5 cells/mL. Three drops of the collagen-cell mixture were placed in each well of a 6-
wellplatein a60 mm dish, andthe plates were allowedto reach37uCi naC O 2incubator
for 1 h. The final concentration was approximately 3 3 10
4 cells/collagen gel droplet.
Culture medium was added to each well, and the plate was incubated in a CO2incubator
at 37uC overnight. The anticancer drugs (i.e., 10 mMA C Ra l o n e ,1 0mM zopolrestat
alone or 10 mM ACR plus 10 mM zopolrestat) were added to the cells for 2 days.
Determination of albumin and alpha fetoprotein (AFP) in the culture media. The
albumin protein concentration was determined by an enzyme-linked
immunosorbent assay (ELISA) using goat anti-human albumin (Cosmo Bio Co.,
Tokyo, Japan). The quantitative analysis of AFP secretion was performed with the
AFP Amerlex-M RIA detection kit (Ortho Clinical Diagnostics, Issy les Moulineaux,
France).
Measurement of oxygen consumption in the liver cancer cells. The oxygen
consumption (mean 6 SD, nmol min
21 mg
21 protein) in the AKR1B10-positive or
negative liver cancer cells was measured by a Clark-type oxygen microelectrode.
Measurements were conducted 3 days after the administration of 10 mM of ACR
alone, 10 mM of zopolrestat alone, and 10 mM of ACR plus 10 mM zopolrestat.
Statisticalanalyses.AllstatisticaltestswereperformedwithDr.SPSSIIforWindows
(SPSS Japan, Inc, Tokyo), and statistical significance was defined as p,0.05.
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